EAEU Adverse Event Monitoring Deadlines of 2, 10 and 30 Days Explained

1. Key takeaways

The Eurasian Economic Union monitoring rules for medical devices set three tiers of reporting deadlines according to the severity of the event: 2 calendar days where the event constitutes a serious threat to health, 10 calendar days where it led to death or an unexpected serious deterioration of health, and 30 calendar days in other cases. These figures come from Union-level rules and are not identical to the statutory deadlines of Belarus as a nation. The distinction is not pedantic: Union figures describe the regional framework that coordinates events across member states, while the national regulation approved by Resolution No. 177 defines the domestic procedure and the domestic recipients. A manufacturer operating in Belarus therefore needs two different mental ledgers — one for the Union framework, which is fully specified in Decision No. 174, and one for the national procedure, whose specific day counts must be confirmed separately and, at the time of writing, remain pending verification in this series.

2. Legal basis

3. Expert insights

Insight 1: the tiering logic of the three deadlines is the severity of the consequence, not the risk class of the product. This point is frequently confused. The tiered deadlines look at what consequence this particular event caused — a serious threat to health, death or an unexpected serious deterioration, or something else — and not at whether the product belongs to class 1 or class 3. The same product may fall under the 2-day deadline in one event and the 30-day deadline in another. Manufacturers therefore need an event-based classification decision table keyed to outcomes, not a product-based table keyed to registration classes, and their reporting personnel must be trained to apply the consequence test to each individual event as it arises rather than memorizing a class-to-deadline mapping.

Insight 2: the Union rules also include an annual reporting requirement for post-market clinical monitoring. Under Decision No. 174, class 3 devices and implantable class 2b devices are subject to post-market clinical monitoring, and an annual report must be submitted before 1 February each year within the prescribed number of years. For manufacturers of high-risk products this is a long-term obligation that is easy to overlook once the registration project has been delivered and the project team has disbanded. A calendar-based reminder owned by the quality function, rather than by the regulatory project team, is the reliable way to keep this duty alive across product life cycles.

Insight 3: an obligation to file a follow-up report remains after urgent corrective measures. After urgent corrective measures are taken, a follow-up report must be submitted within 2 days, and a safety information notice must be published. When manufacturers draft their corrective action plans, the follow-up report and the notice should be embedded as part of the measures themselves — with named owners and deadlines — rather than left as an afterthought to be considered once the field action is complete. Treating them as integral steps also makes the corrective action file more defensible in a later inspection.

Insight 4: Union figures cannot be used directly as the national statutory deadlines of Belarus. The national adverse event procedure is defined by the regulation approved by Resolution No. 177, and its specific day counts have not been obtained in official source text by GRZAN, so this series treats them as pending verification. For submissions made inside Belarus, the national requirements prevail; the Union figures serve to understand the regional framework and to coordinate events across member states. Until the national figures are confirmed in writing, the prudent internal standard is the shortest applicable Union timeline, with the national requirement kept as the formal reference.

4. Practical recommendations

1. Classify by event consequence, not by product class. Build an event grading decision table keyed to outcomes and select the reporting deadline from the table for every single event, with a second-person review before submission.
2. Set an annual report reminder for high-risk products. For class 3 and implantable class 2b devices, configure a recurring reminder ahead of 1 February each year for the post-market clinical monitoring annual report.
3. Embed the follow-up report and the notice in corrective action plans. Name the person responsible for the 2-day follow-up report and for the publication of the safety information notice inside the plan itself.
4. Confirm the national deadlines separately. Obtain written confirmation from the local representative of the number of days in the Belarusian national regulation, and do not import Union figures into national procedure documents.

5. Verification checklist

• □ A decision table graded by event consequence (2 / 10 / 30 days) has been established
• □ An annual report reminder (before 1 February each year) has been set for high-risk products
• □ Corrective action plans include the 2-day follow-up report and the safety information notice
• □ The national reporting day counts for Belarus have been confirmed separately in writing
• □ Awareness is documented that Union figures are not national statutory deadlines

Regulatory information verified as of 30 October 2026.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three fronts. First, distinguishing the applicable conditions and the remaining time windows of the two channels — Union-level unified registration and national registration in each member state. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of 28 April 2026 (state registration number 6-1/55925, in force 1 May 2026): the total time limit for preliminary technical work is compressed to 90 calendar days, the scope list is closed and implementing organizations are prohibited from expanding it, while the window for filing applications under the national procedure takes 31 December 2027 as the key milestone, so path selection must be decided in step with the time window. Second, local authorized representative services: GRZAN acts as the statutory representative of the manufacturer in Belarus, handling registration filings, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has already synchronized its liaison mechanisms after Council of Ministers Resolution No. 378 of 27 July 2026 (in force 30 July 2026) transferred adverse event functions to the State Institution for State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and organizes technical documentation according to the target path — the national path follows the annex to Ministry of Health Resolution No. 55, while the Union path follows Eurasian Economic Commission Council Decision No. 46. For post-market compliance in the Belarusian market — vigilance, recalls and responses to supervisory inspections — GRZAN provides end-to-end support built on the same framework.

Business enquiries: info@grzanglobal.com